Company news

Novavax, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024

November 3, 2024

Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

October 15, 2024

Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU

October 8, 2024

Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

September 24, 2024

Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.

September 12, 2024

Novavax to Participate in Upcoming September Conferences

September 3, 2024

Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

August 29, 2024

Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights

August 7, 2024

Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024

July 31, 2024

Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

June 23, 2024

Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

June 13, 2024

Novavax to Participate in 2024 Jefferies Global Healthcare Conference

May 29, 2024

Novavax to Participate in BofA Securities 2024 Health Care Conference

May 12, 2024

Novavax Reports First Quarter 2024 Financial Results and Operational Highlights

May 9, 2024

Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines

May 9, 2024

Novavax to Host Conference Call to Discuss First Quarter 2024 Financial Results and Operational Highlights on May 10, 2024

May 6, 2024

Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024

March 31, 2024

Novavax to Participate in TD Cowen's 44th Annual Health Care Conference

February 28, 2024

Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

February 27, 2024

Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement

February 21, 2024

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024

February 19, 2024

Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan

December 17, 2023

Novavax's Updated COVID-19 Vaccine Now Authorized in Canada

December 4, 2023

Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization

November 27, 2023

Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities

November 16, 2023

Novavax Reports Third Quarter 2023 Financial Results and Operational Highlights

November 8, 2023

Novavax to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Operational Highlights on November 9, 2023

November 1, 2023

Novavax's Updated Nuvaxovid™ COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

October 30, 2023

Novavax's Updated COVID-19 Vaccine Now Approved in the EU

October 30, 2023

Novavax's Prototype COVID-19 Vaccine Nuvaxovid™ Receives Full Approval in Singapore

October 17, 2023

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ ▼ in United Kingdom

October 17, 2023

Novavax COVID-19 Vaccine Doses Available at Major Retail Pharmacies Across the U.S.

October 12, 2023

Novavax Advances Science Supporting Protein-based Vaccine Technology at IDWeek 2023 and World Vaccine Congress Europe 2023

October 10, 2023

Novavax Launches Choose to Protect™ Campaign to Educate Public About Importance of Updated COVID Vaccination this Fall

October 9, 2023

Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

October 2, 2023

Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6

August 21, 2023

Novavax Reports Second Quarter 2023 Financial Results and Operational Highlights

August 7, 2023

Novavax to Host Conference Call to Discuss Second Quarter 2023 Financial Results and Operational Highlights on August 8, 2023

July 31, 2023

Novavax's Nuvaxovid™ Receives Full Marketing Authorization in the EU for the Prevention of COVID

July 5, 2023

Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall

June 14, 2023

Novavax Announces Adjournment of 2023 Annual Meeting of Stockholders to July 11, 2023

June 14, 2023

Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research

June 4, 2023

Novavax to Participate in the Jefferies Global Healthcare Conference

May 31, 2023

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

May 25, 2023

Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore

May 11, 2023

Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses

May 8, 2023

Novavax Reports First Quarter 2023 Financial Results and Operational Highlights

May 8, 2023

Novavax to Participate in the BofA Securities 2023 Health Care Conference

May 3, 2023

Novavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023

May 1, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 69 decks. Every deck is listed under its year.